https://www.prnewswire.com/news-releases/pfizer-to-acquire-a...About a 60% premium, sold at about 11b market cap. Can't find much on Array right now as their website is down! 😶On Mektovi/braftovi: http://www.bioworld.com/content/array%E2%80%99s-braftovimekt...Another nod for precision medicine!
Coulda, woulda, shoulda....I owned this a few years back. Made a decent return (just under a triple) and sold on news. Somehow fell off my watchlist radar. ARRY buyout price gives Blueprint a blueprint, IMO.Cosmid
Gotta say that at 8b for loxo & 11b for array, BPMC with possibly two drugs on market and 4+ in clinical trials by end of 2020 may put it at the higher end of those valuations, if not above.I think, like your prior views on the LOXO buyout, that I'll be disappointed with anything under 3x from here.
Hi Fuma102, Cosmid,It seems to be hitting a few of your ideas, Tricida up %7.45 also. Probably part of the same trend, although I do see they are soon getting more analyst coverage. Not sure whether to add to BPMC, or spread things out a little. Your picks have been very astute, any thoughts on the current situation?Loops
First, please do your own diligence! Now that that's out of the way...Fwiw, I bought a second chunk of TCDA 5/9 at $35. Initially bought in late March at 23.8 ... I have a hard time believing this isn't a buyout for a reasonable premium as their lead candidate could easily be a blockbuster. No reason why it popped today, but could see it as a harbinger of a buyout.Blueprint I DONT want to get bought out. I can not understate how rare I think this is: the combination of at least one approved drug, plus a good pipeline, plus great FOCUSED leadership, plus some cash on hand.... Is incredibly rare. I've literally never, in 15-20 years, seen a biotech company hit their stated timelines consistently like BPMC.I've steadily accumulated BPMC since march, my 4th largest holding behind MDB, PAYC, & W.I fully believe BPMC is quite undervalued. If I didn't already have so much of it, I'd add more. It's incredibly refreshing to see a biotech this focused and executing.
Loops,I wouldn’t be afraid to buy more of either at this point. That said, if you own just two biotechs I would suggest “spreading it out”. Fuma can get away with it because of he is experienced and savvy enough to focus on the cream of the crop. Cosmid
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |